Drug Profile
HIV stem cell therapy - City of Hope
Latest Information Update: 27 Nov 2019
Price :
$50
*
At a glance
- Originator City of Hope National Medical Center
- Developer Benitec Biopharma; City of Hope National Medical Center
- Class Antivirals; Haematopoietic stem cells therapies; Small interfering RNA
- Mechanism of Action Immunostimulants; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported HIV infections; Lymphoma
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in HIV-infections in USA (IV, Infusion)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Lymphoma in USA (IV, Infusion)
- 21 Nov 2011 Pharmacodynamics data from a phase I trial in HIV infections released by Benitec